Monash, Schering buddy up to research male disorders
27 November, 2003 by Graeme O'NeillMonash University and big German pharmaceutical company Schering AG have announced a collaborative research and licensing agreement to develop new therapies for prostate disease, male infertility, and new male contraceptives.
WEHI opens Bundoora Biotechnology Centre
18 November, 2003 by Melissa TrudingerAustralia's oldest medical research institution, the Walter and Eliza Hall Institute of Medical Research, has made a major move into the biotechnology arena with the opening of its AUD$27.5 million Biotechnology Centre.
Polartechnics in US distribution deal
14 November, 2003 by Melissa TrudingerSydney-based devices company Polartechnics (ASX:PLT) has signed a heads of agreement with US company Open Systems Imaging (OSI) to market and sell its melanoma detection and monitoring system SolarScan in the US.
New clinical trials lab opens for business
13 November, 2003 by Melissa TrudingerMelbourne clinical trials group Cancer Trials Australia (CTA) opened a new state-of-the-art laboratory on Wednesday, to complement other clinical trials services offered by the group.
Progen sells unit to NZ supplier
12 November, 2003 by Melissa TrudingerProgen (ASX:PGL) has sold its life sciences business unit to New Zealand-based Global Science and Technology (GST) for AUD$1.2 million.
'Eating machine' helps ID insulin activity
04 November, 2003 by Graeme O'NeillDiabetes researchers at Sydney's Garvan Institute have identified a gene that plays a key role in cellular sensitivity to insulin -- and which could be a target for anti-obesity drugs.
Peter Mac cancer therapy shows high promise
22 October, 2003 by Graeme O'NeillScientists at Melbourne's Peter MacCallum Cancer Research Centre have demonstrated an ingenious strategy for boosting and focusing the body's immune defences that causes dramatic regression of tumours in mice.
Bionomics files for new breast cancer test patents
21 October, 2003 by Graeme O'NeillAdelaide biotech Bionomics (ASX:BNO) has filed a provisional patent on a new method of determining the prognosis for women with early-stage breast cancer.
Cellestis firms up Japanese deal
20 October, 2003 by Melissa TrudingerDiagnostic company Cellestis has completed an amendment to its distribution agreement with Japanese company Nichirei, covering price and minimum volumes for its second generation TB test QuantiFERON-TB GOLD.
Virax soars on positive Phase II results
16 October, 2003 by Melissa TrudingerVirax's share price (ASX:VHL) soared 28 per cent today on heavy trading after the company released good results for its HIV immunotherapy Phase IIa clinical trial.
GroPep to receive $3.8m at malaria milestone
16 October, 2003 by Melissa TrudingerAdelaide-based biotech GroPep is to receive AUD$3.8 million from the Gates Foundation-funded Malaria Vaccine Initiative (MVI) and the Program for Appropriate Technology in Health (PATH), after meeting the first milestone in a project inherited from Biotech Australia.
ComBio 2003: Hormone shows promise as metabolism regulator
30 September, 2003 by Melissa TrudingerA fat-derived hormone identified using proteomic techniques may have therapeutic uses related to its role as a regulator of lipid metabolism in the liver and arteries.
Pharmaxis reveals IPO plans
26 September, 2003 by Melissa TrudingerPharmaxis has announced plans for a AUD$21 million float on the ASX in October/November.
Blis Technologies aims at Chinese market
23 September, 2003 by Graeme O'NeillDunedin (NZ) biotech company Blis Technologies has opened a portal into a potential $200 million market by signing a deal with Auckland-based Asia Pacific Biotech Distributors (APBD) to take its antibacterial Throat Guard into China.
WEHI team exposes two new anti-cancer targets
19 September, 2003 by Graeme O'NeillCancer researchers in Melbourne and Innsbruck hunting for new options to treat cancer have flushed two promising new therapeutic targets from the genetic thickets of the p53-mediated apoptosis pathway: Puma and Noxa.
